Kimberly Westrich, M.A., chief strategy officer of National Pharmaceutical Council, shares her prediction for 2025.
My big prediction for 2025 is that value will play an increasingly important role in healthcare conversations. One place this will play out is in conversations about the Medicare Prescription Drug Negotiation Program. They will center not only around the unintended consequences of the program for patients but also about whether CMS is thinking about value as [it implements] the program and particularly as CMS releases the concise justifications for the first round of set prices.
Westrich
What evidence they say they considered may impact the incentives for generating value-related, real-world evidence in the future. Another area is that researchers will continue to explore and develop alternative methods that seek to better incorporate the full spectrum of value.
Finally, employers will continue to consider value as they select pharmacy benefits. Data from this year show that those with value-based formularies saved three times as much as those with rebate-based agreements.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
HIV + Hepatitis Institute Welcomes RFK, Talks Importance of Ending the HIV Epidemic
February 13th 2025The group released a statement today expressing that they are eager to work with Robert F. Kennedy Jr. to eradicate HIV when steps into his role as the Secretary of Health and Human Services.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen